FR23C1035I1 - PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE TO TREAT PARKINSON’S DISEASE - Google Patents
PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE TO TREAT PARKINSON’S DISEASEInfo
- Publication number
- FR23C1035I1 FR23C1035I1 FR23C1035C FR23C1035C FR23C1035I1 FR 23C1035 I1 FR23C1035 I1 FR 23C1035I1 FR 23C1035 C FR23C1035 C FR 23C1035C FR 23C1035 C FR23C1035 C FR 23C1035C FR 23C1035 I1 FR23C1035 I1 FR 23C1035I1
- Authority
- FR
- France
- Prior art keywords
- carbidopa
- dopa
- prodrugs
- disease
- treat parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 229960004205 carbidopa Drugs 0.000 title 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066771P | 2014-10-21 | 2014-10-21 | |
| PCT/US2015/056686 WO2016065019A1 (en) | 2014-10-21 | 2015-10-21 | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR23C1035I1 true FR23C1035I1 (en) | 2023-12-08 |
Family
ID=54478240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR23C1035C Active FR23C1035I1 (en) | 2014-10-21 | 2023-09-29 | PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE TO TREAT PARKINSON’S DISEASE |
Country Status (35)
| Country | Link |
|---|---|
| US (7) | US9446059B2 (en) |
| EP (3) | EP3569587A1 (en) |
| JP (5) | JP6567049B2 (en) |
| KR (3) | KR20230066484A (en) |
| CN (4) | CN111362980B (en) |
| AR (1) | AR102389A1 (en) |
| AU (3) | AU2015335941B2 (en) |
| BR (1) | BR112017008198B1 (en) |
| CA (1) | CA2965379A1 (en) |
| CY (1) | CY1121826T1 (en) |
| DK (1) | DK3209302T3 (en) |
| ES (1) | ES2739536T3 (en) |
| FI (1) | FIC20230014I1 (en) |
| FR (1) | FR23C1035I1 (en) |
| HR (1) | HRP20191285T1 (en) |
| HU (2) | HUE044115T2 (en) |
| IL (3) | IL251829B (en) |
| LT (2) | LT3209302T (en) |
| MX (2) | MX2021003840A (en) |
| MY (1) | MY189519A (en) |
| NL (1) | NL301224I2 (en) |
| NO (1) | NO2023013I1 (en) |
| PH (1) | PH12017500746A1 (en) |
| PL (1) | PL3209302T3 (en) |
| PT (1) | PT3209302T (en) |
| RS (1) | RS58972B1 (en) |
| RU (2) | RU2743347C2 (en) |
| SA (1) | SA521421115B1 (en) |
| SG (1) | SG11201703170RA (en) |
| SI (1) | SI3209302T1 (en) |
| TR (1) | TR201908296T4 (en) |
| TW (2) | TWI718999B (en) |
| UA (1) | UA120437C2 (en) |
| WO (1) | WO2016065019A1 (en) |
| ZA (1) | ZA201702760B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231716T1 (en) | 2014-03-13 | 2024-03-15 | Neuroderm Ltd. | Dopa decarboxylase inhibitor compositions |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| SG11201703170RA (en) | 2014-10-21 | 2017-05-30 | Abbvie Inc | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease |
| WO2017184871A1 (en) * | 2016-04-20 | 2017-10-26 | Abbvie Inc. | Carbidopa and l-dopa prodrugs and methods of use |
| WO2017223182A1 (en) * | 2016-06-22 | 2017-12-28 | Medchem Partners, Llc. | Nitric oxide donors |
| WO2018154447A1 (en) * | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| US20180311238A1 (en) * | 2017-04-28 | 2018-11-01 | Saniona A/S | Selective Agonist Of a6 Containing nAChRs |
| WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| GEP20227446B (en) | 2017-11-24 | 2022-12-12 | H Lundbeck As | New catecholamine prodrugs for use in treatment of parkinson's disease |
| CN110294789A (en) * | 2018-03-21 | 2019-10-01 | 海南大学 | The synthetic method of the oligopeptides containing DOPA and its application in terms of anti-Parkinson's disease prodrug |
| AU2019379806A1 (en) * | 2018-11-15 | 2021-05-27 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| WO2020178810A1 (en) * | 2019-03-04 | 2020-09-10 | Neuroderm, Ltd. | Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| WO2020234276A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132171A (en) * | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
| US4016288A (en) * | 1975-08-13 | 1977-04-05 | Merck & Co., Inc. | Compositions and method of treating hypertension |
| DD230865B1 (en) * | 1982-08-09 | 1987-05-20 | Dresden Arzneimittel | PROCESS FOR THE PREPARATION OF HYDRAZINOCARBONSAEUREDERIVATES BY N-AMINATION OF AMINOCARBONSAEUREDERIVATES |
| US4618484A (en) | 1983-03-30 | 1986-10-21 | Yale University | Composition and method for treatment of melanomas |
| US4508706A (en) * | 1983-03-30 | 1985-04-02 | Yale University | Composition for increasing melanin in mammalian skin and hair |
| IT1213182B (en) * | 1984-06-25 | 1989-12-14 | Simes | DERIVATIVES OF COMPOUNDS WITH A CATECOLAMINICAL STRUCTURE. |
| US4616484A (en) | 1984-11-30 | 1986-10-14 | Kysor Industrial Corporation | Vehicle refrigerant heating and cooling system |
| IT1200427B (en) | 1985-03-22 | 1989-01-18 | Afros Spa | PROCESS AND PLANT FOR THE MOLDING OF PIECES IN EXPANDED PLASTIC MATERIAL, WITH SPRAY PREFORMED PARTS OR INSERTS IN THE SAME FORMING MOLD |
| JPH02138A (en) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | L-dopa derivative |
| IT1226727B (en) | 1988-07-29 | 1991-02-05 | Simes | PRECURSOR DRUGS OF DOPAMIN. |
| EP0393781B1 (en) * | 1989-04-20 | 1995-02-08 | ZAMBON GROUP S.p.A. | Dopamine pro-drug |
| GB9102812D0 (en) | 1991-02-11 | 1991-03-27 | Enzymatix Ltd | Compounds |
| IT1255471B (en) | 1992-07-30 | 1995-11-02 | Zambon Spa | CATECOLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| SE9203594D0 (en) | 1992-11-30 | 1992-11-30 | Christer Nystroem | DISPERSA SYSTEM MEDICINAL PRODUCT |
| WO1999024442A1 (en) * | 1997-11-12 | 1999-05-20 | Ariad Pharmaceuticals, Inc. | Novel signal transduction inhibitors, compositions containing them |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| KR20050016449A (en) * | 2002-05-29 | 2005-02-21 | 임팩스 라보라토리즈, 인코포레이티드 | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| MXPA05000028A (en) | 2002-06-20 | 2005-08-26 | Nippon Suisan Kaisha Ltd | Produrg, medicinal utilization thereof and process for producing the same. |
| AU2003293423A1 (en) | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| JP5160786B2 (en) | 2003-08-29 | 2013-03-13 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | Pharmaceutical composition and method of using levodopa and carbidopa |
| ES2360759T3 (en) * | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR USE OF LEVODOPA AND CARBIDOPA. |
| AU2004285532A1 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Administration of levodopa and carbidopa |
| AU2005252220B2 (en) * | 2004-06-04 | 2011-06-02 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
| ES2402552T3 (en) | 2004-07-06 | 2013-05-06 | Abbott Laboratories | HIV protease inhibitor prodrugs |
| KR101396639B1 (en) * | 2005-12-05 | 2014-05-21 | 제노포트 인코포레이티드 | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| MX2008015339A (en) * | 2006-05-31 | 2008-12-16 | Solvay Pharm Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa. |
| CA2654557A1 (en) * | 2006-06-16 | 2007-12-21 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and l-dopa |
| CA2673336A1 (en) | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| GB0713189D0 (en) | 2007-07-06 | 2007-08-15 | Proximagen Ltd | Amino acid derivatives |
| EP2252284B1 (en) * | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| JP5757864B2 (en) | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | Water-soluble acetaminophen analogue |
| AU2010250766B2 (en) | 2009-05-19 | 2015-04-09 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| WO2011056240A2 (en) | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| WO2011109767A2 (en) | 2010-03-04 | 2011-09-09 | University Of Notre Dame Du Lac | Gelatinase inhibitors and prodrugs |
| PT2640358T (en) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| PT2647619E (en) | 2010-12-02 | 2015-02-20 | Ono Pharmaceutical Co | Novel compound and medical use thereof |
| BR112013014304A2 (en) | 2010-12-10 | 2016-07-19 | Synagile Corp | subcutaneously infusible levodopa prodrug compositions and method of infusion |
| WO2012158527A2 (en) * | 2011-05-13 | 2012-11-22 | Howmedica Osteonics | Organophosphorous & multivalent metal compound compositions & methods |
| HRP20211442T1 (en) | 2013-03-13 | 2022-02-04 | Neuroderm Ltd | Combination for the treatment of parkinson’s disease |
| WO2014139161A1 (en) | 2013-03-15 | 2014-09-18 | Techfields Pharma Co., Ltd. | Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases |
| SG11201703170RA (en) | 2014-10-21 | 2017-05-30 | Abbvie Inc | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease |
| MA41377A (en) | 2015-01-20 | 2017-11-28 | Abbvie Inc | LEVODOPA AND CARBIDONA INTESTINAL GEL AND PROCEDURES FOR USE |
| WO2017184871A1 (en) | 2016-04-20 | 2017-10-26 | Abbvie Inc. | Carbidopa and l-dopa prodrugs and methods of use |
| US20190224153A1 (en) | 2016-09-29 | 2019-07-25 | Berlirem Gmbh | L-dopa derivatives for the treatment of neurological diseases |
| WO2018154447A1 (en) | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
-
2015
- 2015-10-21 SG SG11201703170RA patent/SG11201703170RA/en unknown
- 2015-10-21 ES ES15791424T patent/ES2739536T3/en active Active
- 2015-10-21 PT PT15791424T patent/PT3209302T/en unknown
- 2015-10-21 RU RU2017117413A patent/RU2743347C2/en active
- 2015-10-21 PL PL15791424T patent/PL3209302T3/en unknown
- 2015-10-21 DK DK15791424.3T patent/DK3209302T3/en active
- 2015-10-21 CN CN202010123543.8A patent/CN111362980B/en active Active
- 2015-10-21 EP EP19164151.3A patent/EP3569587A1/en not_active Withdrawn
- 2015-10-21 EP EP22204022.2A patent/EP4186510A1/en active Pending
- 2015-10-21 TR TR2019/08296T patent/TR201908296T4/en unknown
- 2015-10-21 CN CN202010250046.4A patent/CN111454290B/en active Active
- 2015-10-21 LT LTEP15791424.3T patent/LT3209302T/en unknown
- 2015-10-21 AU AU2015335941A patent/AU2015335941B2/en active Active
- 2015-10-21 RU RU2021103000A patent/RU2021103000A/en unknown
- 2015-10-21 MY MYPI2017701367A patent/MY189519A/en unknown
- 2015-10-21 JP JP2017521517A patent/JP6567049B2/en active Active
- 2015-10-21 KR KR1020237015051A patent/KR20230066484A/en not_active Application Discontinuation
- 2015-10-21 SI SI201530761T patent/SI3209302T1/en unknown
- 2015-10-21 TW TW104134601A patent/TWI718999B/en active
- 2015-10-21 TW TW110101738A patent/TWI755257B/en active
- 2015-10-21 US US14/919,418 patent/US9446059B2/en active Active
- 2015-10-21 BR BR112017008198-9A patent/BR112017008198B1/en active IP Right Grant
- 2015-10-21 MX MX2021003840A patent/MX2021003840A/en unknown
- 2015-10-21 HU HUE15791424 patent/HUE044115T2/en unknown
- 2015-10-21 UA UAA201704815A patent/UA120437C2/en unknown
- 2015-10-21 EP EP15791424.3A patent/EP3209302B1/en active Active
- 2015-10-21 CN CN202010250040.7A patent/CN111494395B/en active Active
- 2015-10-21 AR ARP150103412A patent/AR102389A1/en unknown
- 2015-10-21 WO PCT/US2015/056686 patent/WO2016065019A1/en active Application Filing
- 2015-10-21 MX MX2017005236A patent/MX2017005236A/en unknown
- 2015-10-21 RS RS20190854A patent/RS58972B1/en unknown
- 2015-10-21 KR KR1020177013734A patent/KR102537018B1/en active IP Right Grant
- 2015-10-21 CA CA2965379A patent/CA2965379A1/en not_active Abandoned
- 2015-10-21 CN CN201580069519.8A patent/CN107206013A/en active Pending
- 2015-10-21 KR KR1020247023761A patent/KR20240113982A/en active Search and Examination
-
2016
- 2016-07-21 US US15/216,009 patent/US20160362431A1/en not_active Abandoned
-
2017
- 2017-04-19 ZA ZA2017/02760A patent/ZA201702760B/en unknown
- 2017-04-20 SA SA521421115A patent/SA521421115B1/en unknown
- 2017-04-20 IL IL251829A patent/IL251829B/en active IP Right Grant
- 2017-04-21 PH PH12017500746A patent/PH12017500746A1/en unknown
- 2017-09-26 US US15/715,245 patent/US10174061B2/en active Active
-
2018
- 2018-12-05 US US16/210,996 patent/US10730895B2/en active Active
-
2019
- 2019-07-17 HR HRP20191285TT patent/HRP20191285T1/en unknown
- 2019-07-19 CY CY20191100771T patent/CY1121826T1/en unknown
- 2019-07-30 JP JP2019139442A patent/JP6750076B2/en active Active
- 2019-08-23 IL IL268885A patent/IL268885B/en active IP Right Grant
-
2020
- 2020-05-04 US US16/866,400 patent/US11091507B2/en active Active
- 2020-08-04 IL IL276493A patent/IL276493A/en unknown
- 2020-08-11 JP JP2020135560A patent/JP6932227B2/en active Active
-
2021
- 2021-03-04 AU AU2021201414A patent/AU2021201414B2/en active Active
- 2021-07-16 US US17/378,321 patent/US20220153765A1/en not_active Abandoned
- 2021-08-16 JP JP2021132161A patent/JP2021183628A/en active Pending
-
2022
- 2022-10-24 US US17/971,836 patent/US20230106081A1/en not_active Abandoned
-
2023
- 2023-02-20 HU HUS2300009C patent/HUS2300009I1/en unknown
- 2023-03-20 NO NO2023013C patent/NO2023013I1/en unknown
- 2023-03-24 NL NL301224C patent/NL301224I2/en unknown
- 2023-03-31 FI FIC20230014C patent/FIC20230014I1/en unknown
- 2023-06-08 LT LTPA2023519C patent/LTPA2023519I1/lt unknown
- 2023-08-04 AU AU2023210650A patent/AU2023210650A1/en active Pending
- 2023-09-29 FR FR23C1035C patent/FR23C1035I1/en active Active
- 2023-10-06 JP JP2023174083A patent/JP2023174770A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1035I1 (en) | PRODRUGS OF CARBIDOPA AND L-DOPA AND THEIR USE TO TREAT PARKINSON’S DISEASE | |
| FR22C1011I2 (en) | PRODRUGS OF FUMARATES AND THEIR USE FOR THE TREATMENT OF VARIOUS DISEASES | |
| IL286888A (en) | Use of pridopidine to treat depression or anxiety | |
| GB2551642B (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| MA41028A (en) | METHODS AND FORMULATIONS FOR THE TREATMENT OF VASCULAR EYE PATHOLOGIES | |
| EA201691582A1 (en) | NEW PHARMACEUTICAL PREPARATIONS | |
| EP3464638A4 (en) | Use of biomarkers in determining susceptibility to disease treatment | |
| DK3125882T3 (en) | TREATMENT OF METABOLIC DISORDERS IN ANIMAL ANIMALS | |
| HK1243636A1 (en) | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| IL259153A (en) | Use of proteasome inhibitors to treat ocular disorders | |
| GB201716240D0 (en) | Relevancy assessment and visualization of biological pathways | |
| MA40687A (en) | VASCULAR MALFORMATION TREATMENT METHODS AND COMPOSITIONS | |
| PT3393517T (en) | Treatment of moderate to severe influenza | |
| FR3021546B1 (en) | COSMETIC ASSEMBLY FOR THE TREATMENT OF KERATIN FIBERS | |
| BR112016028653A2 (en) | methods of treating neurodevelopmental diseases and disorders | |
| FR3030270B1 (en) | COSMETIC TREATMENT PROCESS AND KIT THEREFOR | |
| FI20146137A (en) | Heat treatment of nanofibril cellulose hydrogel | |
| HK1244223A1 (en) | Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation | |
| EP3534932C0 (en) | Treatment of diseases related to igfb3 and its receptor | |
| FR3016881B1 (en) | TREATMENT OF DEGENERESCENCES AND PHOTO-INDUCED LESIONS OF THE RETINA | |
| FR3021548B1 (en) | COSMETIC ASSEMBLY FOR THE TREATMENT OF KERATIN FIBERS | |
| DK3200785T3 (en) | TREATMENT OF PAROXYSMAL EXTREME Pain Relief | |
| GB201516437D0 (en) | Compositions and methods relating to the treatment of disease | |
| AU365751S (en) | An exercise device |